BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

...DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting CDK7, a cell cycle regulator, could treat small cell lung cancer...
BioCentury | Nov 21, 2019

Epigenetic protein YTHDF1 identified as NSCLC target

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting YTHDF1, a protein that controls translation of several cell cycle regulators, could treat non-small cell lung cancer (NSCLC). YTHDF1 protein and mRNA levels were higher in tumor tissue...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...pathway deficiency in AML ( No. 178 ), and inhibition of chromatin reader BRD4 and cell cycle regulator...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
BioCentury | Aug 24, 2017
Emerging Company Profile

Heartfelt WISPER

...other tissues, where it plays roles in cellular proliferation and wound healing. CCNA2 is a cell cycle regulator...
BioCentury | Jun 17, 2017
Product Development

I-SPY adapts

The Phase III failure of the first targeted therapy to graduate from I-SPY 2 does not mean the platform trial wasn’t able to predict the correct outcome. What it does mean is that I-SPY 2...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Seeing the wood for the trees

A survey of molecular targets mentioned in abstracts from next week’s meeting of the American Association for Cancer Research (AACR) suggests the field has not abandoned its roots in cellular proliferation, growth hormone and DNA...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
BioCentury | Mar 31, 2016
Translation in Brief

Slow and steady

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bind Therapeutics Inc. (NASDAQ:BIND) have joined forces to stretch the therapeutic index of a kinase inhibitor that had stumbled in the clinic. The partners developed a nanoparticle formulation that slowed...
Items per page:
1 - 10 of 46